长春高新子公司两款药品新纳入国家医保目录

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has two products newly included in the National Medical Insurance Directory for 2025, which may enhance the company's market position and revenue potential [1] Group 1: Company Developments - Changchun Jinsai Pharmaceutical's self-developed product, Jinsai Zeng (now known as Jintai Growth Hormone Injection), has been added to the national medical insurance directory [1] - The product Meishiya (known as Acetate Medroxyprogesterone Oral Suspension) has also been included in the national medical insurance directory through collaboration [1]